

for regular cardiometabolic monitoring in high-risk patients, including anyone prescribed long-term antipsychotic medication. Periodic checks were already part of routine care but the literature suggests this practice was inadequate. Systematic monitoring is an improvement but still not adequate on its own. Systematic testing must be tied to clear treatment options and also clear lines of responsibility.

Declaration of interest

M.D.H has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory boards of AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck JA, Pfizer and Sanofi Aventis.

- 1 Bell R, Farmer S, Ries R, Srebnik D. Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. *Psychiatr Serv* 2009; **60**: 1686–9.
- 2 Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. *Psychol Med* 2012; **42**: 125–47.

- 3 Kusumi I, Ito K, Honda M, Hayashishita T, Uemura K, Hashimoto N, et al. Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data. *Psychiatry Clin Neurosci* 2011; **65**: 349–55.
- 4 Kusumi I, Ito K, Uemura K, Honda M, Hayashishita T, Miyamoto K, et al. Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a 1-year follow-up study. *Prog Neuropsychopharmacol Biol Psychiatry* 2011; **35**: 1922–6.

Marc De Hert, MD, PhD, University Psychiatric Centre, KU Leuven, campus Kortenberg Leuvensesteenweg 517, 3070 Kortenberg, Belgium. Email: marc.de.hert@uc-kortenberg.be; **Davy Vancampfort**, PT, MSc, University Psychiatric Centre, KU Leuven campus Kortenberg, Leuvensesteenweg, Kortenberg and Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Catholic University Leuven, Heverlee, Belgium; **Christoph U. Correll**, The Zucker Hillside Hospital, Glen Oaks, and Albert Einstein College of Medicine, Bronx, New York, USA; **Joseph Peuskens**, MD, PhD, K. Sweers, RN, University Psychiatric Centre, KUL campus Kortenberg, Leuvensesteenweg, Kortenberg, Belgium; **Ruud van Winkel**, MD, PhD, University Psychiatric Centre, KU Leuven campus Kortenberg, Leuvensesteenweg, Kortenberg, Belgium, and Department of Psychiatry and Neuropsychology, EURON, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands; **Alex J. Mitchell**, MRCPsych, Leicester General Hospital, Leicester Partnership Trust, and Department of Cancer & Molecular Medicine, Leicester Royal Infirmary, University of Leicester, UK

doi: 10.1192/bjp.201.1.76

Correction

Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans. *BJP*, **199**, 391–397. Figure 3 (p. 394): blue diamonds should be labelled ‘BAL+cocaine’. Online Table DS1, the headings of columns five and six for parts (b) to (d) should read: (b) ‘BP_{ND} values on nutritionally balanced amino acid mixture + cocaine test, mean (s.d.)’ and ‘% change BP_{ND} induced by acute tryptophan depletion + cocaine, mean (s.d.)’; (c) ‘BP_{ND} values on nutritionally balanced amino acid mixture + placebo test, mean (s.d.)’ and ‘% change BP_{ND} induced by acute tryptophan depletion + cocaine, mean (s.d.)’; (d) ‘BP_{ND} values on nutritionally balanced amino acid mixture, mean (s.d.)’ and ‘% change BP_{ND} induced by acute tryptophan depletion, mean (s.d.)’.

doi: 10.1192/bjp.201.1.77